GGrantIndex
← Leaderboards

David Ko

University Of Southern California

$2,344,909
Attributed
$2,344,909
Total exposure
11
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$2,344,909 · 11

By mechanism

M01$2,344,909 · 11

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectBrain Disorder ChemotherapyClinical ResearchHuman Therapy EvaluationAnticonvulsantsPartial SeizureDrug Screening /EvaluationPharmacokineticsEpilepsyClinical Trial Phase ICombination ChemotherapyDrug InteractionsQuality Of LifeGeneralized SeizuresTriazoles

Grant awards (49)

GABAPENTIN MONOTHERAPY TRIAL--MULTICENTER STUDY TO DETERMINE EFFICACY$0
M01 · FY2002 · RR
SD 204269 AS ADD ON THERAPY FOR PATIENTS W/ COMPLEX PARTIAL SEIZURES$0
M01 · FY2002 · RR
SB 204269 AS ADD ON THERAPY IN PARTIAL SEIZURE PTS$0
M01 · FY2002 · RR
PATIENTS W/ REFRACTORY PARTIAL SEIZURES$0
M01 · FY2002 · RR
RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2002 · RR
534U87 IN PATIENTS W/ EPILEPSY$0
M01 · FY2002 · RR
SB204269 AS ADD ON TX IN REFRACTORY PARTIAL SEIZURES$0
M01 · FY2002 · RR
RUFINAMIDE--EFFICACY AND SAFETY AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES$0
M01 · FY2002 · RR
EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF ADD ON 534487 IN EPILEPSY$0
M01 · FY2002 · RR
534U87 IN PATIENTS W/ EPILEPSY$155,764
M01 · FY2001 · RR
GABAPENTIN MONOTHERAPY TRIAL--MULTICENTER STUDY TO DETERMINE EFFICACY$155,764
M01 · FY2001 · RR
EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF ADD ON 534487 IN EPILEPSY$155,764
M01 · FY2001 · RR
RUFINAMIDE--EFFICACY AND SAFETY AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES$155,764
M01 · FY2001 · RR
SB204269 AS ADD ON TX IN REFRACTORY PARTIAL SEIZURES$155,764
M01 · FY2001 · RR
RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS W/ PARTIAL SEIZURES$155,764
M01 · FY2001 · RR
PATIENTS W/ REFRACTORY PARTIAL SEIZURES$155,764
M01 · FY2001 · RR
SB 204269 AS ADD ON THERAPY IN PARTIAL SEIZURE PTS$155,764
M01 · FY2001 · RR
SD 204269 AS ADD ON THERAPY FOR PATIENTS W/ COMPLEX PARTIAL SEIZURES$155,764
M01 · FY2001 · RR
534U87 IN PATIENTS W/ EPILEPSY$0
M01 · FY2001 · RR
SB 204269 AS ADD ON THERAPY IN PARTIAL SEIZURE PTS$0
M01 · FY2001 · RR
RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2001 · RR
EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF ADD ON 534487 IN EPILEPSY$0
M01 · FY2001 · RR
RUFINAMIDE--EFFICACY AND SAFETY AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES$0
M01 · FY2001 · RR
SB204269 AS ADD ON TX IN REFRACTORY PARTIAL SEIZURES$0
M01 · FY2001 · RR
PATIENTS W/ REFRACTORY PARTIAL SEIZURES$0
M01 · FY2001 · RR
GABAPENTIN MONOTHERAPY TRIAL--MULTICENTER STUDY TO DETERMINE EFFICACY$0
M01 · FY2001 · RR
SD 204269 AS ADD ON THERAPY FOR PATIENTS W/ COMPLEX PARTIAL SEIZURES$0
M01 · FY2001 · RR
EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF ADD ON 534487 IN EPILEPSY$155,764
M01 · FY2000 · RR
GABAPENTIN MONOTHERAPY TRIAL--MULTICENTER STUDY TO DETERMINE EFFICACY$155,764
M01 · FY2000 · RR
534U87 IN PATIENTS W/ EPILEPSY$155,764
M01 · FY2000 · RR
SB204269 AS ADD ON TX IN REFRACTORY PARTIAL SEIZURES$155,764
M01 · FY2000 · RR
SD 204269 AS ADD ON THERAPY FOR PATIENTS W/ COMPLEX PARTIAL SEIZURES$35,553
M01 · FY2000 · RR
534U87 IN PATIENTS W/ EPILEPSY$35,553
M01 · FY2000 · RR
SB204269 AS ADD ON TX IN REFRACTORY PARTIAL SEIZURES$35,553
M01 · FY2000 · RR
RUFINAMIDE--EFFICACY AND SAFETY AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES$35,553
M01 · FY2000 · RR
EVALUATION OF SAFETY, TOLERABILITY AND EFFICACY OF ADD ON 534487 IN EPILEPSY$35,553
M01 · FY2000 · RR
GABAPENTIN MONOTHERAPY TRIAL--MULTICENTER STUDY TO DETERMINE EFFICACY$35,553
M01 · FY2000 · RR
RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS W/ PARTIAL SEIZURES$35,553
M01 · FY2000 · RR
PATIENTS W/ REFRACTORY PARTIAL SEIZURES$35,553
M01 · FY2000 · RR
SB 204269 AS ADD ON THERAPY IN PARTIAL SEIZURE PTS$35,553
M01 · FY2000 · RR
RUFINAMIDE ADJUNCT THERAPY IN GENERALIZED TONIC-CLONIC S$0
M01 · FY2000 · RR
RUFINAMIDE ADJUNCT THERAPY IN GENERALIZED TONIC-CLONIC S$0
M01 · FY2000 · RR
RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2000 · RR
SD 204269 AS ADD ON THERAPY FOR PATIENTS W/ COMPLEX PARTIAL SEIZURES$0
M01 · FY2000 · RR
RUFINAMIDE--EFFICACY AND SAFETY AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES$0
M01 · FY2000 · RR
RUFINAMIDE ADJUNCT THERAPY IN PRIMARY GENERALIZED SEIZUR$0
M01 · FY2000 · RR
PATIENTS W/ REFRACTORY PARTIAL SEIZURES$0
M01 · FY2000 · RR
RUFINAMIDE ADJUNCT THERAPY IN PRIMARY GENERALIZED SEIZUR$0
M01 · FY2000 · RR
SB 204269 AS ADD ON THERAPY IN PARTIAL SEIZURE PTS$0
M01 · FY2000 · RR